Canada markets open in 4 hours 12 minutes

PAVmed Inc. (PAVM)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
1.8800+0.0200 (+1.08%)
At close: 04:00PM EDT
1.8709 -0.03 (-1.53%)
After hours: 04:05PM EDT

PAVmed Inc.

360 Madison Avenue
25th Floor
New York, NY 10017
United States
212 949 4319
https://www.pavmed.com

Sector(s)Healthcare
IndustryMedical Devices
Full Time Employees107

Key Executives

NameTitlePayExercisedYear Born
Dr. Lishan Aklog M.D.Chairman & CEO945.09kN/A1966
Mr. Dennis M. McGrath CPAPresident, CFO & Corporate Secretary663.38kN/A1957
Mr. Shaun M. O'Neill M.B.A.Executive VP & COO447.47kN/A1983
Dr. Brian J. deGuzman M.D.Executive VP, Chief Technology & Compliance Officer427.6kN/A1965
Dr. Suman M. Verma M.D., Ph.D.Senior VP of Molecular Genetics & Chief Scientific OfficerN/AN/AN/A
Michael ParksVice President of Investor RelationsN/AN/AN/A
Mr. Michael Adam GordonExecutive VP, General Counsel & SecretaryN/AN/A1974
Dr. Deepika A. Lakhani Ph.D.Senior VP, Chief Regulatory & Quality OfficerN/AN/AN/A
Dr. Victoria T. Lee M.D.Senior VP & Chief Medical OfficerN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

Corporate Governance

PAVmed Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.